"Shock Doctrine" author Naomi Klein says Republicans may try to turn the Houston flood disaster into a rationale for expanding fossil fuel development.
Big Pharma's primary trade association created a "ghost corporation" to spend millions of dollars — from hidden corporate donors —
against an Ohio ballot measure aimed at lowering drug costs.
Sen. Cory Gardner, the beneficiary of fossil fuel cash, criticized Colorado towns for trying to restrict oil and gas development in residential neighborhoods.
The Trump White House let an Obama-era ethics rule lapse. As a result, at least nine administration officials oversee offices that are the target of lobbying efforts by companies they recently worked for.
Chicago's parking meters, Texas' State Highway 130, Virginia's Elizabeth River tunnels — where did they go wrong? Hint: The devil is in the (contractual) details.
After the deadly white nationalist rally in Charlottesville, companies are severing ties with racist and anti-Semitic websites, removing their ads or online infrastructure.
Within four minutes, the president can launch nuclear weapons from a “Denny’s menu of nuclear war” and there are no checks on that authority.
Vice President Mike Pence has been directly lobbied by major health care and drug companies, Wall Street firms, oil and gas interests and industry groups interested in shaping a federal infrastructure privatization initiative.
The White House said National Economic Council Director Gary Cohn would recuse himself from matters directly affecting his old employer, Goldman Sachs. But groups Goldman is a member of have been directly lobbying the NEC.
Axon is using body cameras to build an artificial intelligence system that raises big civil liberties questions.
Dozens of firms, many of them foreign, are hiring lobbyists to get an edge over rivals when it comes to the White House's infrastructure plans. Several of them have prior connections to the officials they're lobbying.
At various levels of government — federal agency leaders, state offices, Congress — individuals have taken steps to protect the pharmaceutical industry at the expense of sick consumers.
While serving as education secretary, DeVos has continued to invest in a company accused of making misleading claims about its ability to treat ADHD and autism.
The Blackwater founder is trying to sell the Trump administration on a plan to privatize the U.S. war effort in Afghanistan — an approach that could benefit his current company, a security contractor aligned with the Chinese government.
Mike Pence’s handling of privatization deals for Indiana roads reveals how the vice president might shape the administration’s $1 trillion plan to rebuild America. Who would profit, and who would pay?
New York’s $192 billion pension fund put forward a shareholder resolution that would’ve forced Cardinal Health to demonstrate that its products weren’t being used in lethal injections. Regulators stood in the way.
Drug manufacturers use U.S. tax dollars for research and then charge the world’s highest prices to U.S. consumers. Sanders and King — the two senators who don’t belong to either party — have introduced a mechanism to block them.
Adjustments to the corporate income tax rate have little impact on how much companies actually pay, says a new study: Closing loopholes matters more.
Renowned climatologist Michael Mann says market mechanisms worked well in addressing environmental problems — until players like the Koch brothers made climate change a partisan issue.
As the Democratic party battles over single-payer health care, Lt. Gov. Donna Lynne, a former Kaiser Permanente exec, may enter the party’s race for governor of Colorado.
The super PAC affiliated with Mitch McConnell is pouring cash from the finance and fossil fuel industries into a Senate Republican primary race in Alabama, backing candidate Luther Strange.
Corporate handout? Government interference in the market? As Wisconsin holds its first public hearing on the $3 billion Foxconn deal, both liberal and conservative analysts expressed objections.
Fossil fuel and pharmaceutical donations flooded into a super PAC that boosts state legislative elections. That could help the GOP counter the unpopularity of the Trump administration and keep control of state governments.
Connecticut Gov. Dannel Malloy opposed a bill to curb drug price fraud — while insurance and pharma money poured into his governors' association and his insurance commissioner maintained a close relationship with the industry.
The Democratic Governors Association received contributions from nearly two dozen pharmaceutical companies in the first half of 2017, including some that are being sued by states for their alleged role in the opioid epidemic.
A new Congressional Budget Office analysis shows that a bill introduced by Sanders and Senate Democrats allowing foreign drug imports would save the federal government $6 billion. But other Democrats aren't onboard.
Gov. Scott Walker’s deal gives Foxconn — which admitted dumping chemicals in a Chinese river — an exemption from statutes that protect Wisconsin wetlands.
Business advocacy organizations and Koch-affiliated political groups have been gearing up for tax reform — spending millions to influence it.
Wisconsin state representative Chris Taylor attended ALEC’s annual conference to find out what bills Corporate America is pushing — and she told IBT why the group wants a new constitutional convention.
New York Gov. Cuomo and Mayor de Blasio are giving the insurance giant millions in tax breaks to persuade the company to move its headquarters. Does this kind of deal benefit taxpayers?